Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam plus metronidazole versus meropenem in pediatric complicated intra-abdominal infection
2014-003242-28Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2015
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Intra-abdominal infection (IAI) comparing ceftazidime-avibactam plus metronidazole with meropenem (2 arms). Primary endpoint: Safety and tolerability. Started Feb 2015; status: completed.
02
Drugs
ceftazidime + avibactammetronidazolemeropenem
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2014-003242-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003242-28.